PTC Therapeutics | PTCT - Sales Revenues


PTC Therapeutics reported $164.7M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Cytokinetics USD 17.76M 15.83M Dec/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Incyte USD 1.51B 140M Dec/2025
Ionis Pharmaceuticals USD 203M 46M Dec/2025
Ironwood Pharmaceuticals USD 47.71M 74.35M Dec/2025
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025
Xencor USD 28.24M 7.24M Dec/2025